Next month we'll get the full accounts so it should be crystal clear then what the receivables situation is. I've no problem with using revenue as a growth barometer so long as they're accounting for the revenue correctly & the aging of any debt doesn't get out of hand.
Repeat orders were always going to be the critical test of this business, the product is an easy sell based on the 'story' but the user experience is crucial to it's success as to whether they come back for more.
I'd like to hear more on how the NHS trial is progressing.
ZNO Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
